p. 2851−2857
2090-7125
Vol.71/No.4
p. 2858−2868
2090-7125
Vol.71/No.4
p. 2869−2874
2090-7125
Vol.71/No.4
p. 2875−2884
2090-7125
Vol.71/No.4
p. 2885−2891
2090-7125
Vol.71/No.4
p. 2892−2906
2090-7125
Vol.71/No.4
0.5) between nifedipine and placebo groups regarding maternal age, gestational age, parity, Previous preterm labor and Inter pregnancy interval (years). While, there was statistically significant difference (P ≤ 0.05) regarding mode of delivery, delivery time and medications side effects, neonatal respiratory distress and neonatal Intensive care unit (NICU) admission in both group. Additionally, onset of labor between 34-37 week was significantly less frequent in nifedipine group than placebo group.
Conclusion: we found that the superiority of nifedipine as prophylactic tocolosysis in the mean prolongation of pregnancy compared to that of placebo in high risk women for preterm labor, it has better effect on neonatal outcomes, fewer maternal side effects. We would only comment that nifedipine looks like a promising drug in this regard and further large studies are required to establish this fact. ]]>
p. 2907−2912
2090-7125
Vol.71/No.4
p. 2913−2915
2090-7125
Vol.71/No.4
p. 2916−2925
2090-7125
Vol.71/No.4
p. 2926−2931
2090-7125
Vol.71/No.4
p. 2932−2943
2090-7125
Vol.71/No.4
p. 2944−2949
2090-7125
Vol.71/No.4
p. 2956−2959
2090-7125
Vol.71/No.4
p. 2960−2962
2090-7125
Vol.71/No.4
p. 2963−2973
2090-7125
Vol.71/No.4
p. 2974−2981
2090-7125
Vol.71/No.4
p. 2982−2988
2090-7125
Vol.71/No.4
0.05) and a significant increase in estimated fetal weight by ultrasound (P<0.05), and was associated with a significant decrease in neonatal ICU admission (P=0.218) and neonatal mortality (P=0.290). Conclusion: Sildenafil citrate can improve utero-placental perfusion and length of pregnancy in pregnancies complicated by IUGR. It appears to have a significantly positive effect on fetal weight. Sildenafil treatment may offer a new opportunity to improve perinatal outcomes, for pregnancies complicated by IUGR. However these observations require further studies on wide scale. ]]>
p. 2989−2995
2090-7125
Vol.71/No.4
p. 2996−3000
2090-7125
Vol.71/No.4
p. 3001−3006
2090-7125
Vol.71/No.4
p. 3007−3016
2090-7125
Vol.71/No.4
p. 3017−3024
2090-7125
Vol.71/No.4
p. 3025−3031
2090-7125
Vol.71/No.4
p. 3032−3038
2090-7125
Vol.71/No.4
p. 3039−3048
2090-7125
Vol.71/No.4
p. 3049−3055
2090-7125
Vol.71/No.4
p. 3056−3060
2090-7125
Vol.71/No.4
p. 3061−3065
2090-7125
Vol.71/No.4
p. 3066−3078
2090-7125
Vol.71/No.4